| Revenue growth | 17% YoY for FY26; high-teens guided for FY27. |
|---|---|
| Margins | Record 33.7% in Q4; FY27 guided at 24%+. |
| Demand visibility | Strong momentum in India chronic and international markets. |
| Management confidence | High; citing structural strength and innovation pipeline. |
Growth
FY26 revenue grew 17% to ₹271.5bn; PAT up 15% to ₹54.6bn. Q4 revenue grew 16% YoY to ₹75.9bn.
Outlook
FY27 guidance: high-teens revenue growth and 24%+ EBITDA margins. ₹1,500cr capex planned for FY27.
Risks
Potential pricing deflation in chronic segments and increased competitive intensity in key US products like Revlimid and Mirabegron.
Earnings Call filed with NSE, NSE: ZYDUSLIFE. Summary written with AI assistance from the document.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,203.90
- Market cap
- ₹1,21,141 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.8×Sector 50.4×
- Promoter holding
- 75.01%+0.01% QoQ
- FII holding
- 6.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Business Update
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
Zydus Lifesciences Credit Rating
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences Legal & Regulatory
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
- Value
- ₹55.46 Cr
Zydus Lifesciences Earnings Call Transcript: Key Takeaways
Zydus delivered robust FY27 Q1 results driven by strong India-branded formulations and U.S. generic resilience.
- Call
- Guides 10% growth
Zydus Lifesciences Investor Presentation: Key Takeaways
Zydus Lifesciences reported strong Q1 FY27 revenue growth of 22% YoY, driven by robust performance in India and International formulations, despite a decline in PAT and EBITDA margins.
Zydus Lifesciences Q1 FY27 Results: Net Profit ₹939.8 Cr, Down 35.9% YoY
Zydus Lifesciences Ltd reported revenue from operations of ₹8,017 Cr (+22.0% YoY) and net profit of ₹939.8 Cr (-35.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹939.8 Cr · -35.9% YoY